Dr. Judy Lieberman, M.D., Ph.D. is Professor of pediatrics at the Harvard Medical School, Director of the Division of AIDS at Harvard Medical School and a senior investigator in the Immune Disease Institute. Dr. Lieberman is board certified in internal medicine and hematology, a widely known expert in translational medicine and a pioneer in the therapeutic use of RNAi, particularly through the development of innovative delivery tools. Dr. Lieberman and her colleagues are working to harness RNAi for use against HIV and other viruses and they have developed novel strategies for cell-specific targeting of small interfering RNAs to confer in vivo protection from viral disease. In related work, Dr. Lieberman's laboratory is also working in the emerging field of miRNAs by developing their potential as diagnostic and therapeutic tools. She has been Member of the Scientific Advisory Board of Cequent Pharmaceuticals, Inc. since October 2008. She serves as Member of the Scientific Advisory Board at Alnylam Pharmaceuticals Inc. Dr. Lieberman received a Ph.D. in theoretical physics from Rockefeller University and completed her M.D. in the joint Harvard-MIT Program in Health, Science and Technology.

 pediatrics research